Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we report the development of an orally bioavailable SARS-CoV-2 3C-lik...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiangrui, Su, Haixia, Shang, Weijuan, Zhou, Feng, Zhang, Yan, Zhao, Wenfeng, Zhang, Qiumeng, Xie, Hang, Jiang, Lei, Nie, Tianqing, Yang, Feipu, Xiong, Muya, Huang, Xiaoxing, Li, Minjun, Chen, Ping, Peng, Shaoping, Xiao, Gengfu, Jiang, Hualiang, Tang, Renhong, Zhang, Leike, Shen, Jingshan, Xu, Yechun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575921/
https://www.ncbi.nlm.nih.gov/pubmed/37833261
http://dx.doi.org/10.1038/s41467-023-42102-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575921/
https://www.ncbi.nlm.nih.gov/pubmed/37833261
http://dx.doi.org/10.1038/s41467-023-42102-y

Ejemplares similares